Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir.
about
Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS.Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized TherapyRole of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitorsHuman biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison.The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant VirusDrug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
P2860
Q33860320-99EDDEDA-49BF-4B89-B03B-33377F8B2A96Q36628396-CA7856BB-814C-4EB6-B74F-F9AB14DF10B8Q37263541-A74F9936-ED13-4904-A2D0-92C390FC9239Q37263885-4CE5B7AC-976B-4933-BF41-29A7CE143BCEQ37547275-F08462DB-6C73-4972-9EDC-B682436A94F4Q37550710-36ACB150-1812-49A9-8FDC-134BE9564CFEQ40218320-AA1DFB2E-0751-46EB-A1BC-03EAB6FAD165Q52596192-6AFC6DC4-8AE5-4D2D-BB86-C3F1CFB64F5B
P2860
Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Combination therapies, effecti ...... e, rilpivirine, and tenofovir.
@ast
Combination therapies, effecti ...... e, rilpivirine, and tenofovir.
@en
type
label
Combination therapies, effecti ...... e, rilpivirine, and tenofovir.
@ast
Combination therapies, effecti ...... e, rilpivirine, and tenofovir.
@en
prefLabel
Combination therapies, effecti ...... e, rilpivirine, and tenofovir.
@ast
Combination therapies, effecti ...... e, rilpivirine, and tenofovir.
@en
P2860
P356
P1476
Combination therapies, effecti ...... e, rilpivirine, and tenofovir.
@en
P2093
Mark A Wainberg
P2860
P356
10.2147/HIV.S32377
P407
P577
2013-02-05T00:00:00Z